Azenta Successfully Completes Full Repayment of $35 Million Vendor Loan

Azenta, Inc. (Nasdaq: AZTA), a prominent player in the life sciences sector, recently declared the successful repayment of a $35 million vendor loan. This secured loan was established during the company's sale of B Medical Systems S.à r.l. to Thelema S.à r.l., which concluded on July 1, 2026. The announcement came on September 4, 2026, marking a significant financial milestone for the company.

The transaction saw Azenta Germany GmbH, a wholly owned subsidiary of Azenta, providing a secured term loan in the amount of $35 million. This loan was backed by a pledge over the equity interests of B Medical Systems. With the recent repayment, the loan has been cleared in full prior to its maturity date, along with the accrued interest. In addition to the financial settlement, the share pledge collateralizing the loan has been released.

Dr. Martin D. Madaus, the Interim President and CEO of Azenta, expressed that the full repayment of the vendor loan signifies the completion of the divestiture of B Medical Systems. He emphasized, "Azenta has now received the entire purchase price in cash, and the credit exposure associated with the transaction has been retired, supporting our disciplined approach to capital allocation."

The total cash received from the sale, amounting to $63 million, includes the proceeds from the vendor loan repayment. This move not only enhances Azenta's financial standing but also allows for more strategic capital allocation within its operational framework. Such well-timed fiscal actions illustrate Azenta's commitment to maintaining a sound financial posture in the competitive life sciences industry.

Azenta, headquartered in Burlington, Massachusetts, operates globally, delivering comprehensive life sciences solutions. The firm aids organizations in bringing groundbreaking therapies and solutions to market more efficiently, leveraging its expertise across drug development, clinical research, and advanced cell therapies. Among its renowned brands are GENEWIZ, FluidX, and Barkey, which underpin the company's operational excellence in the cold-chain sample management and multiomics services.

The company's recent financial maneuvers not only highlight its ability to manage vendor financing effectively but also reflect a strategic focus on increasing shareholder value and minimizing debt exposure. As the life sciences landscape continues to evolve, Azenta's sound financial practices and commitment to innovation position it favorably for future growth opportunities.

Investors and market analysts will be keenly observing Azenta’s next steps in its capital allocation strategies, particularly in enhancing its service offerings and exploring new markets for growth. The overall operational effectiveness demonstrated thus far points to a robust approach in navigating industry challenges while capitalizing on emerging opportunities.

In conclusion, the successful completion of the loan repayment is a testament to Azenta's robust financial management and strategic forward planning. It sets a solid foundation for future initiatives and maintains investor confidence in the company’s capabilities as a leader in the life sciences domain.

For more details on Azenta's services and corporate developments, visit www.azenta.com.